1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

628.50
INR
-11.75
(-1.84%)
13.11EPS
42.10P/E
57.08BMarket Cap
Bliss GVS Pharma Limited
BSE:BLISSGVS
(Bombay Stock Exchange)

Recent

price

628.50

P/E

ratio

42.10

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
21.22
25.89
38.45
33.41
39.47
53.02
36.57
35.27
85.94
66.11
55.13
71.41
72
73.42
76.28
87.17
94.37
Revenue per Share
3.94
5.09
5.6
3.97
5.81
8
7.95
5.7
11.99
9.43
6.64
1.46
6.83
7.23
8.02
12.23
12.79
Basic EPS, GAAP
1.68
1.85
-1.29
-1.58
0.92
9.66
18.01
-1.03
-0.37
-1.22
5.32
5.95
-5.73
7.14
2.8
7.75
- -
Free Cash Flow per Basic Share
0.94
0.76
0.8
0.47
0.83
0.6
0.61
0.72
0.8
1.21
0.54
0.52
0.52
0.52
0.51
1.01
- -
Dividend per Share
16.15
20.42
25.01
27.81
32.68
39.78
47.18
51.99
62.63
71.32
78.36
78.97
84.87
92.39
99.68
112.76
- -
Book Value per Share
15.52
19.96
17.62
20.59
25.45
35.48
42.42
51
61.64
70.51
77.56
78.19
84.1
91.64
98.93
112.01
- -
Tangible Book Value per Share
103
103
103
103
103
103
103
103
103
103
103
103
104
104
105
106
107
Basic Weighted Avg Shares
2,188
2,671
3,966
3,446
4,071
5,469
3,772
3,638
8,864
6,819
5,687
7,379
7,474
7,659
8,018
9,206
10,052
Sales/Revenue/Turnover
-12.98
25.01
26.51
17.57
24.51
26.14
25.79
24.04
18.03
16.68
16
16.01
13.48
17.59
12.19
17.28
15.14
Operating Margin (%)
55
36
61
112
123
143
206
214
89
126
172
173
187
264
294
335
352
Depreciation Expense
406
525
577
410
599
825
820
588
1,237
973
685
150
709
755
843
1,291
1,362
Net Income, GAAP
23.31
33.85
45.58
41.85
36.06
32.42
41.39
50.43
30.37
26.14
28.96
57.3
27.66
30.2
28.16
28.94
29.82
Effective Tax Rate (%)
18.57
19.67
14.55
11.89
14.71
15.08
21.75
16.16
13.96
14.26
12.04
2.04
9.48
9.85
10.51
14.03
13.55
Profit Margin (%)
1,453
1,498
1,467
1,616
1,744
2,170
1,288
3,904
4,866
5,392
5,616
5,438
5,041
6,535
6,517
7,108
- -
Working Capital
82
376
913
876
573
457
256
59
325
402
344
267
434
449
326
133
- -
LT Debt
1,666
2,107
2,718
2,970
3,520
4,436
5,530
5,477
6,599
7,504
8,279
8,465
9,174
10,030
10,918
12,318
- -
Total Equity
-13.8
20.59
17.4
8.28
12.92
17.05
7.31
3.56
14.39
8.82
6.98
1.24
7.39
6.47
6.33
7.7
- -
Return on Invested Capital (%)
26.78
25.73
16.86
11.94
14.97
13.72
8.26
4.56
17.33
12.74
7.37
0.86
6.82
6.9
7.25
10.37
- -
Return on Capital (%)
27.1
27.85
24.63
15.05
19.2
22.07
18.3
11.49
20.93
14.08
8.87
1.85
8.32
8.15
8.36
11.51
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
84
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
133
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
106
106
Market Capitalization
17,296
22,803
57,085

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,463
- -
Cash, Cash Equivalents & STI
- -
1,891
- -
Accounts Receivable, Net
- -
5,172
- -
Inventories
- -
1,507
- -
Total Current Liabilities
- -
2,355
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
84
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.98%
8.32%
12.81%
Free Cash Flow
-68.29%
-58.39%
178.47%
Net Income, GAAP
39.51%
72.9%
53.18%
Sales/Revenue/Turnover
12.24%
10.61%
14.82%
Total Cash Common Dividend
- -
- -
97.17%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,836
2,177
2,104
1,980
8,018
2026
2,075
2,444
2,183
2,570
9,206
2027
2,856
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.97
2.31
2.27
1.47
8.02
2026
4.08
2.58
2.2
3.27
12.23
2027
4.73
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.51
2026
- -
- -
- -
- -
1.01
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations with a focus on suppositories and pessaries, where it ranks as the world's largest producer; its product portfolio encompasses capsules, creams, gels, ointments, dry powders for injection, effervescent tablets, eye/ear drops, nasal solutions, lotions, lozenges, oral solids, balms, nasal inhalers, soaps, roll-ons, shampoos, powders, sprays, and petroleum jelly, spanning therapeutic areas including anti-malarials, anti-inflammatories, antibiotics, antifungals, and gynaceological treatments under brands such as ANOMEX, GACET, LONART, VAGID, and GVZOLE. The company, founded in 1984 and headquartered at 102 Hyde Park, Saki Vihar Road, Andheri East, Mumbai, India, operates cGMP-compliant manufacturing facilities certified by US FDA, EU GMP, WHO GMP, TGA, Health Canada, and regulators from over 25 countries, enabling exports to global markets across emerging and developed regions. It also provides contract manufacturing services (CMO/CDMO), finished dosage forms, and active pharmaceutical ingredients to serve diverse healthcare needs. In recent developments, Bliss GVS Pharma granted 553,000 employee stock options in November 2025 at a 72% discount under its ESOP 2019 plan to enhance retention; accepted the resignation of Managing Director Gagan Harsh Sharma effective immediately and appointed Shreekrishna Joshi as Head-Legal and Senior Management Personnel with 15 years of expertise; and allotted 75,250 shares under the same ESOP while approving unaudited financial results for the half-year ended September 30, 2025, reflecting ongoing strategic workforce and leadership transitions amid revenue of INR 8.60 billion.